A report revealed that a patient with recurrent multifocal glioblastoma who received multiple intracavitary injections of IL13Rα2-targeted CAR-T cells experienced no significant toxic side effects and obtained a significant response (38). The gene discussed is IL13RA2; the disease is glioblastoma.